Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22
Published . Updated .
The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revised to $8.22 / share. This is an increase of 27.91% from the prior estimate of $6.43 dated September 13, 2026. These figures represent aggregate analyst targets c
Directly affected
- IPHA Innate Pharma
Named in this report.
Indirectly affected
- JPM JPMorgan Chase
Bank profits move with lending and interest rates
- BAC Bank of America
Bank profits move with lending and interest rates
- WFC Wells Fargo
Bank profits move with lending and interest rates
- C Citigroup
Bank profits move with lending and interest rates
- GS Goldman Sachs
Bank profits move with lending and interest rates
- MS Morgan Stanley
Bank profits move with lending and interest rates
- XLF Financial Select Sector SPDR
A fund of financial companies
- KBE SPDR S&P Bank
A fund of bank stocks
- KRE SPDR S&P Regional Banking
Regional banks are sensitive to deposits and rates
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revised to $8.22 / share. This is an increase of 27.91% from the prior estimate of $6.43 dated September 13, 2026. These figu…
Source: Nasdaq Markets
Price since this story was published: Innate Pharma (IPHA)
Since the first closing price after “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22,” Innate Pharma (IPHA) is -11.28%. The S&P 500 fund (SPY) is -1.08% over the same days, a -10.20% difference versus the market.
Filings that name Innate Pharma (IPHA) around 2 Oct 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 3 days before publication, inside 30 days. The filing is listed beside the story “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 21 days before publication, inside 30 days. The filing is listed beside the story “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Innate Pharma (IPHA)
Companies carried with this story
- IPHA Innate Pharma
For “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22,” Innate Pharma (IPHA) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names INNATE PHARMA S A in the headline; GA resolved that company to IPHA
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Innate Pharma (IPHA)
The 2 Oct 2026 story “Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22” names Innate Pharma (IPHA) because of this story.
Innate Pharma (IPHA) is on the page because The reported development directly names INNATE PHARMA S A in the headline; GA resolved that company to IPHA
Acadia Healthcare (ACHC) is here too. Its reason reads: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Innate Pharma (IPHA) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. IPHA traded between 1.45 and 1.64 across 13 sessions. The latest close on file is 1.46.
What the saved facts support for Innate Pharma (IPHA)
46 out of 100
“Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.